中国药物评价
  • 中国核心期刊（遴选）数据库收录期刊
  • 中文科技期刊数据库收录期刊
  • 中国期刊全文数据库收录期刊
  • 中国学术期刊综合评价数据库统计源期刊等

• 药品评价-循证医学研究 • 上一篇    下一篇

依达拉奉与尼莫地平治疗颅脑损伤的间接Meta分析

马骏捷,徐丹妮,马爱霞   

  1. 中国药科大学国际医药商学院,中国药科大学国际医药商学院,中国药科大学国际医药商学院
  • 收稿日期:2014-04-18 修回日期:2014-06-12 出版日期:2014-08-25 发布日期:2014-08-25

Comparison Between Edaravone and Nimodipine in Treating Head Injury: An Indirect Meta-analysis

  1. School of International Pharmaceutical Business of China Pharmaceutical University,School of International Pharmaceutical Business of China Pharmaceutical University,
  • Received:2014-04-18 Revised:2014-06-12 Online:2014-08-25 Published:2014-08-25

摘要： 目的：系统评价依达拉奉和尼莫地平治疗颅脑损伤的疗效。方法：以间接Meta分析的方法对已有研究进行合并，系统评价两种药物治疗颅脑损伤的GOS恢复良好率。结果：依达拉奉和尼莫地平的GOS恢复良好率分别为70.57%和64.24%。结论：在治疗颅脑损伤GOS恢复良好率方面，依达拉奉优于尼莫地平。

Abstract: Objective: To systematically evaluate the efficacy of curative effects of treating carniocerebral trauma between Edaravone and Nimodipine. Methods: GOS good recovery rate was taken as effectiveness indicator. An indirect Meta-analysis was developed. Results: The GOS good recovery rate is 70.57% and 64.24% for Edaravone and Nimodipine respecttively. Conclusion: The research showed that GOS good recovery rate in Edaravone arm is better than that in Nimodipine arm.

京公网安备 11010202010539号

您是本站第位访问者

版权所有:《中国药物评价》编辑部     京ICP备05064905号-6

本系统由北京玛格泰克科技发展有限公司设计开发 技术支持：support@magtech.com.cn